Completed PHASE2 INTERVENTIONAL 4-arm NCT00370981

Exploratory Study of Pagoclone in Men With Premature Ejaculation.

A Four-arm, Randomized, Double-blind, Parallel, Placebo-controlled Exploratory Study of Pagoclone 0.15mg, 0.30mg, and 0.60mg in Men With Primary Premature Ejaculation.

Sponsor: Endo Pharmaceuticals

Conditions Premature Ejaculation

Interventions pagoclone

Updated 7 times since 2017 Last updated: Dec 3, 2013 Started: Jul 31, 2006 Primary completion: Jul 31, 2006 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Premature Ejaculation, this trial is completed. The trial is conducted by Endo Pharmaceuticals and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Endo Pharmaceuticals

Data source: Endo Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Aventura, United States , Charlotte, United States , Denver, United States , Edmond, United States , Fort Wayne, United States , Garden City, United States , Homewood, United States , Houston, United States , Indianapolis, United States and 5 more locations